{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:34:18Z","timestamp":1756384458752},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5422","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T22:10:28Z","timestamp":1451599828000},"page":"25-30","source":"Crossref","is-referenced-by-count":9,"title":["Pyoderma Gangrenosum with Ulcerative Colitis Successfully Treated by the Combination of Granulocyte and Monocyte Adsorption Apheresis and Corticosteroids"],"prefix":"10.2169","volume":"55","author":[{"given":"Masashi","family":"Ohno","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Kusatsu General Hospital, Japan"},{"name":"Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Koyama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Kusatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ohara","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Kusatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Shimamoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Kusatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Kusatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyasu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Kusatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Mitsuru","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Kusatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Andoh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shiga University of Medical Science, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 40 (Suppl 2): S253-S259, 2008.","DOI":"10.1016\/S1590-8658(08)60534-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96: 1116-1122, 2001.","DOI":"10.1111\/j.1572-0241.2001.03756.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 31: 307-327, 2002.","DOI":"10.1016\/S0889-8553(01)00019-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 10: 585-595, 2013.","DOI":"10.1038\/nrgastro.2013.117"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 43: 790-800, 2004.","DOI":"10.1111\/j.1365-4632.2004.02128.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Callen JP. Pyoderma gangrenosum. Lancet 351: 581-585, 1998.","DOI":"10.1016\/S0140-6736(97)10187-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases 1: 74-78, 2013.","DOI":"10.12998\/wjcc.v1.i2.74"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. Ther Apher Dial 11: 177-182, 2007.","DOI":"10.1111\/j.1744-9987.2007.00424.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 30: 322-329, 1995.","DOI":"10.1007\/BF02347507"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 47: 2349-2353, 2002.","DOI":"10.1023\/A:1020159932758"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sakanoue M, Takeda K, Kawai K, Kanekura T. Granulocyte and monocyte adsorption apheresis for refractory skin diseases due to activated neutrophils, psoriasis, and associated arthropathy. Ther Apher Dial 17: 477-483, 2013.","DOI":"10.1111\/1744-9987.12113"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yoshino T, Nakase H, Minami N, et al. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis 46: 219-226, 2014.","DOI":"10.1016\/j.dld.2013.10.011"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 104: 2990-2995, 2009.","DOI":"10.1038\/ajg.2009.453"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ohmori T, Yamagiwa A, Nakamura I, Nishikawa K, Saniabadi AR. Treatment of pyoderma gangrenosum associated with Crohn's disease. Am J Gastroenterol 98: 2101-2102, 2003.","DOI":"10.1111\/j.1572-0241.2003.07657.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mori S, Nagashima M, Yoshida K, et al. Granulocyte adsorptive apheresis for leg ulcers complicated by rheumatoid arthritis: a report on three successfully treated cases. Int J Dermatol 43: 732-735, 2004.","DOI":"10.1111\/j.1365-4632.2004.01986.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol 151: 1090-1092, 2004.","DOI":"10.1111\/j.1365-2133.2004.06249.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kanekura T, Kawahara K, Maruyama I, Kanzaki T. Treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis. Ther Apher Dial 9: 292-296, 2005.","DOI":"10.1111\/j.1744-9987.2005.00284.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Okuma K, Mitsuishi K, Hasegawa T, Tsuchihashi H, Ogawa H, Ikeda S. A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apher Dial 11: 387-390, 2007.","DOI":"10.1111\/j.1744-9987.2007.00498.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Watanabe Y, Yamada H. Leukocyte adsorption apheresis for the treatment of pyoderma gangrenosum. J Dermatol 35: 792-794, 2008.","DOI":"10.1111\/j.1346-8138.2008.00572.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hanafusa T, Azukizawa H, Umegaki N, Tani M, Yamaguchi Y, Katayama I. Clinical implications of leukocytapheresis using a centrifugal cell separator for steroid-resistant pyoderma gangrenosum associated with inflammatory bowel disease. J Dermatol 38: 507-510, 2011.","DOI":"10.1111\/j.1346-8138.2010.01009.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion 86 (Suppl 1): 28-35, 2012.","DOI":"10.1159\/000341950"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Argüelles-Arias F, Castro-Laria L, Lobatón T, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci 58: 2949-2954, 2013.","DOI":"10.1007\/s10620-013-2762-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sinagra E, Orlando A, Renna S, Maida M, Cottone M. Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don't forget the role of cyclosporin. Inflamm Bowel Dis 18: E1594-E1595, 2012.","DOI":"10.1002\/ibd.21915"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55: 505-509, 2006.","DOI":"10.1136\/gut.2005.074815"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Imaeda H, Bamba S, Takahashi K, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol 49: 674-682, 2014.","DOI":"10.1007\/s00535-013-0829-7"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Epple HJ. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis 27: 555-559, 2009.","DOI":"10.1159\/000233297"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Fukuchi T, Nakase H, Ubukata S, et al. Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naive Japanese patients with early-diagnosed Crohn's disease. BMC Gastroenterol 13: 124, 2013.","DOI":"10.1186\/1471-230X-14-124"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16: 1-9, 2001.","DOI":"10.1002\/jca.1000"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/1\/55_55.5422\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T03:46:19Z","timestamp":1567482379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/1\/55_55.5422\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5422","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}